Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020): 12.2
Age-standardized cervical cancer incidence per 100 000 women (2020): 21.8
Cumulative risk of cervical cancer, ages 0-74 (2020): 2.5%
Cervical cancer deaths (2019): 230
Cervical cancer mortality-to-incidence ratio (2020): 0.75
Population-based cancer registry exists (2021): No

Primary Prevention

<table>
<thead>
<tr>
<th>Programme coverage</th>
<th>Coverage by age 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>no data</td>
<td>no data</td>
</tr>
</tbody>
</table>

HPV vaccination programme (2020):
- HPV included in national vaccination programme: No
- Scale of vaccination programme: -
- Year of introduction: -
- Primary target cohort: -

Related risk factors:
- Tobacco use prevalence, women aged 15+ years (2020): ND
- Condom use at last high-risk sex (-): ND
- HIV incidence per 1000, women aged 15+ years (2020): ND

Secondary Prevention

National screening programme for cervical cancer exists (2021): No
Primary screening test used (2021): -
Target age range of programme (2021): -
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

Screening for cervical cancer (2019):
- Screened in last 5 years:
  - No
- Ever screened:
  - No

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): No

Cancer diagnosis and treatment services generally available (2021):
- Cancer centre or cancer department at tertiary level: Yes
- Pathology services (laboratories): Yes
- Cancer surgery: Yes
- Chemotherapy: Yes
- Radiotherapy: No

Palliative care for patients with NCDs in the public health system generally available (2021):
- In primary health care facilities: No
- In community or home-based care: No

WHO Cervical Cancer Elimination Strategy Targets for 2030

- 90% of girls fully vaccinated with the HPV vaccine by the age of 15
- 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
- 90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.